JP2024521757A - 新規なアシル化インスリンアナログ - Google Patents

新規なアシル化インスリンアナログ Download PDF

Info

Publication number
JP2024521757A
JP2024521757A JP2023572618A JP2023572618A JP2024521757A JP 2024521757 A JP2024521757 A JP 2024521757A JP 2023572618 A JP2023572618 A JP 2023572618A JP 2023572618 A JP2023572618 A JP 2023572618A JP 2024521757 A JP2024521757 A JP 2024521757A
Authority
JP
Japan
Prior art keywords
cooh
oeg
human insulin
insulin analogue
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521757A5 (enExample
Inventor
バオイェ・ジェン
ダン・レイ
ハイガン・ワン
シュシャン・リン
ジジュ・ジャン
チアン・ワン
チウヤン・リウ
ヤンリン・フ
ジラン・ヤン
ヤン・ジアン
ウェンジア・リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2024521757A publication Critical patent/JP2024521757A/ja
Publication of JP2024521757A5 publication Critical patent/JP2024521757A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023572618A 2021-05-24 2022-05-23 新規なアシル化インスリンアナログ Pending JP2024521757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110570030.6 2021-05-24
CN202110570030 2021-05-24
PCT/CN2022/094392 WO2022247773A1 (en) 2021-05-24 2022-05-23 A novel acylated insulin analog

Publications (2)

Publication Number Publication Date
JP2024521757A true JP2024521757A (ja) 2024-06-04
JP2024521757A5 JP2024521757A5 (enExample) 2025-06-03

Family

ID=84115321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572618A Pending JP2024521757A (ja) 2021-05-24 2022-05-23 新規なアシル化インスリンアナログ

Country Status (8)

Country Link
US (1) US20240374692A1 (enExample)
EP (1) EP4347632A4 (enExample)
JP (1) JP2024521757A (enExample)
KR (1) KR20240013778A (enExample)
CN (1) CN115385843A (enExample)
AU (1) AU2022283328A1 (enExample)
CA (1) CA3217734A1 (enExample)
WO (1) WO2022247773A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121219311A (zh) * 2023-05-24 2025-12-26 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法
CN118063589A (zh) * 2024-02-04 2024-05-24 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535851A (ja) * 2007-08-15 2010-11-25 ノボ・ノルデイスク・エー／エス アシル及びアルキレングリコール部分を有するインスリンアナログ
JP2011515358A (ja) * 2008-03-18 2011-05-19 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
JP2012502083A (ja) * 2008-09-12 2012-01-26 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
JP2015501819A (ja) * 2011-12-15 2015-01-19 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヒト・インスリン類似体及びそのアシル化誘導体
JP2017502074A (ja) * 2013-10-07 2017-01-19 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
JP2017508741A (ja) * 2014-02-28 2017-03-30 ノヴォ ノルディスク アー／エス リシン２２のイプシロン位においてアシル化された、Ａ２２Ｋ、ｄｅｓＢ２７、Ｂ２９Ｒ、ｄｅｓＢ３０ヒトインスリン類似体
JP2017538682A (ja) * 2014-11-14 2017-12-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫修飾因子として有用な大環状ペプチド
JP2018531900A (ja) * 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
JP2019526537A (ja) * 2016-08-02 2019-09-19 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンまたはそのアナログのアシル化誘導体
JP2020117542A (ja) * 2020-05-07 2020-08-06 ノヴォ ノルディスク アー／エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
JP2021512124A (ja) * 2018-02-01 2021-05-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヒトインスリンアナログのアシル化誘導体を含有する医薬組成物及びその調製方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125765A2 (en) * 2005-05-26 2006-11-30 Novo Nordisk A/S Acylated insulin with high purity
WO2007104737A1 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
US20150111820A1 (en) * 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535851A (ja) * 2007-08-15 2010-11-25 ノボ・ノルデイスク・エー／エス アシル及びアルキレングリコール部分を有するインスリンアナログ
JP2011515358A (ja) * 2008-03-18 2011-05-19 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
JP2012502083A (ja) * 2008-09-12 2012-01-26 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
JP2015501819A (ja) * 2011-12-15 2015-01-19 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヒト・インスリン類似体及びそのアシル化誘導体
JP2017502074A (ja) * 2013-10-07 2017-01-19 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
JP2017508741A (ja) * 2014-02-28 2017-03-30 ノヴォ ノルディスク アー／エス リシン２２のイプシロン位においてアシル化された、Ａ２２Ｋ、ｄｅｓＢ２７、Ｂ２９Ｒ、ｄｅｓＢ３０ヒトインスリン類似体
JP2017538682A (ja) * 2014-11-14 2017-12-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫修飾因子として有用な大環状ペプチド
JP2018531900A (ja) * 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
JP2019526537A (ja) * 2016-08-02 2019-09-19 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンまたはそのアナログのアシル化誘導体
JP2021512124A (ja) * 2018-02-01 2021-05-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヒトインスリンアナログのアシル化誘導体を含有する医薬組成物及びその調製方法
JP2020117542A (ja) * 2020-05-07 2020-08-06 ノヴォ ノルディスク アー／エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THOMAS B. KJELDSEN ET AL.: ""Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 1, JPN6026008081, 28 December 2020 (2020-12-28), pages 616 - 628, ISSN: 0005808103 *
THOMAS B. KJELDSEN ET AL.: ""Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Adminis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 13, JPN6026008082, 4 May 2021 (2021-05-04), pages 8942 - 8950, ISSN: 0005808104 *

Also Published As

Publication number Publication date
US20240374692A1 (en) 2024-11-14
WO2022247773A1 (en) 2022-12-01
EP4347632A4 (en) 2025-03-26
EP4347632A1 (en) 2024-04-10
KR20240013778A (ko) 2024-01-30
CA3217734A1 (en) 2022-12-01
AU2022283328A1 (en) 2023-11-16
CN115385843A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
JP2024521757A (ja) 新規なアシル化インスリンアナログ
DK172211B1 (da) Basisk modificeret insulin-derivat
JP2606915B2 (ja) 新規インシュリン誘導体
JPH05504336A (ja) ペプチド誘導体，その製法，これを含む医薬品及び緑内障の治療法
ES2611040T3 (es) Derivados de insulina
JP7432361B2 (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
WO2019200594A1 (zh) 酰化的glp-1衍生物
EP4079757A1 (en) Acylated oxyntomodulin peptide analog
EP4534553A1 (en) Human amylin analog, and derivative and use thereof
WO2013037267A1 (zh) 利拉鲁肽变构体及其缀合物
CN113214382A (zh) 酰化的glp-1衍生物
KR20200038502A (ko) 신규한 아실화 인슐린 유사체 및 이의 용도
CN106554404B (zh) 艾塞那肽修饰物及其用途
WO2020228610A1 (zh) 多肽衍生物及其制备方法
JP2008546816A (ja) エキセンディン４ポリペプチドフラグメントおよびその使用
CN113121649B (zh) 一种新型两亲性蛋白、其制备方法及用途
WO1992015611A1 (en) Novel insulin derivatives
CN103379919A (zh) 瘦蛋白衍生物
KR20250177378A (ko) Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
CN111909255A (zh) 胰岛素衍生物及其制备方法
HK1255297A1 (en) Acylated derivative of human insulin or analogue thereof
HK1255297B (en) Acylated derivative of human insulin or analogue thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303